Best of the Week
Most Popular
1. US Housing Market House Prices Bull Market Trend Current State - Nadeem_Walayat
2.Gold and Silver End of Week Technical, CoT and Fundamental Status - Gary_Tanashian
3.Stock Market Dow Trend Forecast - April Update - Nadeem_Walayat
4.When Will the Stock Market’s Rally Stop? - Troy_Bombardia
5.Russia and China Intend to Drain the West of Its Gold - MoneyMetals
6.BAIDU (BIDU) - Top 10 Artificial Intelligence Stocks Investing To Profit from AI Mega-trend - Nadeem_Walayat
7.Stop Feeding the Chinese Empire - ‘Belt and Road’ Trojan Horse - Richard_Mills
8.Stock Market US China Trade War Panic! Trend Forecast May 2019 Update - Nadeem_Walayat
9.US China Trade Impasse Threatens US Lithium, Rare Earth Imports - Richard_Mills
10.How to Invest in AI Stocks to Profit from the Machine Intelligence Mega-trend - Nadeem_Walayat
Last 7 days
Technical Analyst: Gold Price Weakness Should Be Short Term - 24th May 19
Silver Price Looking Weaker than Gold - 24th May 19
Nigel Farage's Brexit Party EU Elections Seats Results Forecast - 24th May 19
Powerful Signal from Gold GDX - 24th May 19
Eye Opening Currency Charts – Why Precious Metals Are Falling - 23rd May 19
Netflix Has 175 Days Left to Pull Off a Miracle… or It’s All Over - 23rd May 19
Capitalism Works, Ravenous Capitalism Doesn’t - 23rd May 19
The Euro Is Bidding Its Time: A Reversal at Hand? - 23rd May 19
Gold Demand Rose 7% in Q1 2019. A Launching Pad Higher for Gold? - 23rd May 19
Global Economic Tensions Translate Into Oil Price Volatility - 22nd May 19
The Coming Pension Crisis Is So Big That It’s a Problem for Everyone - 22nd May 19
Crude Oil, Hot Stocks, and Currencies – Markets III - 22nd May 19
The No.1 Energy Stock for 2019 - 22nd May 19
Brexit Party and Lib-Dems Pull Further Away from Labour and Tories in Latest Opinion Polls - 22nd May 19
The Deep State vs Donald Trump - US vs Them Part 2 - 21st May 19
Deep State & Financial Powers Worry about Alternative Currencies - 21st May 19
Gold’s Exciting Boredom - 21st May 19
Trade War Fears Again, Will Stocks Resume the Downtrend? - 21st May 19
Buffett Mistake Costs Him $4.3 Billion This Year—Here’s What Every Investor Can Learn from It - 21st May 19
Dow Stock Market Trend Forecast 2019 May Update - Video - 20th May 19
A Brief History of Financial Entropy - 20th May 19
Gold, MMT, Fiat Money Inflation In France - 20th May 19
WAR - Us versus Them Narrative - 20th May 19
US - Iran War Safe-haven Reasons to Own Gold - 20th May 19
How long does Google have to reference a website? - 20th May 19
Tory Leadership Contest - Will Michael Gove Stab Boris Johnson in the Back Again? - 19th May 19
Stock Market Counter-trend Rally - 19th May 19
Will Stock Market “Sell in May, Go Away” Lead to a Correction… or a Crash? - 19th May 19
US vs. Global Stocks Sector Rotation – What Next? Part 1 - 19th May 19
BrExit Party EarthQuake Could Win it 150 MP's at Next UK General Election! - 18th May 19
Dow Stock Market Trend Forecast 2019 May Update - 18th May 19
US Economy to Die a Traditional Death… Inflation Is Going to Move Higher - 18th May 19
Trump’s Trade War Is Good for These 3 Dividend Stocks - 18th May 19
GDX Gold Mining Stocks Fundamentals Update - 17th May 19
Stock Markets Rally Hard – Is The Volatility Move Over? - 17th May 19
The Use of Technical Analysis for Forex Traders - 17th May 19
Brexit Party Set to Storm EU Parliament Elections - Seats Forecast - 17th May 19
Is the Trade War a Catalyst for Gold? - 17th May 19
This Is a Recession Indicator No One Is Talking About—and It’s Flashing Red - 17th May 19
War! Good or Bad for Stocks? - 17th May 19
How Many Seats Will Brexit Party Win - EU Parliament Elections Forecast 2019 - 16th May 19
It’s Not Technology but the Fed That Is Taking Away Jobs - 16th May 19
Learn to Protect your Forex Trading Capital - 16th May 19
Gold Ratio Charts Offer The Keys to the Bull Market - 16th May 19
Is Someone Secretly Smashing the Stock Market at Night? - 16th May 19

Market Oracle FREE Newsletter

Category: BioTech

The analysis published under this category are as follows.

Companies

Monday, June 30, 2014

How to Tap Big Profits in That "Other" Bioscience Niche / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.

And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.

But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.

Read full article... Read full article...

 


Companies

Wednesday, June 18, 2014

Not Even Washington's Meddling Could Stop Biotech’s Biggest Comeback / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.”

Somewhat ironically, a rollover in the biotech market was one of the proximate causes of the overall selloff in tech earlier this year.

And now I’m recommending that you invest in the company that purportedly “caused” the biotech market to roll over in the first place.

Read full article... Read full article...

 


Companies

Tuesday, June 10, 2014

Profit From the "Scariest Event" in Bioscience / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs-down for an experimental drug as it makes its way through the regulatory process.

Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

Read full article... Read full article...

 


Companies

Saturday, May 24, 2014

Healing the Blind… and Boosting Your Stocks Portfolio / Companies / BioTech

By: Casey_Research

By Chris Wood, Senior Analyst

Vision is one of the most important elements of our life, if not the most important one. A 2010 survey by Surge Research found that 60% of Americans are more afraid of blindness than of heart disease, the primary killer of both men and women in the United States.

Read full article... Read full article...

 


Companies

Friday, May 23, 2014

Four Telltale Signs of a Bioscience "Blockbuster" Biotech Stock in the Making / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

Read full article... Read full article...

 


Companies

Wednesday, April 30, 2014

Biotech - New Melanoma Therapies Are Ready for Primetime / Companies / BioTech

By: TLSReport

Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes. In this interview with The Life Sciences Report, Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's University Hospital, illuminates some of the new paradigms being developed in the treatment of this deadly skin cancer. Along the way, he spotlights interesting work in the field.

The Life Sciences Report: You have been a principal investigator in several different clinical trials exploring skin cancers and their metastatic manifestations. Because of your position at a major teaching institution, do you see mostly advanced-stage or late-stage patients? Are you ever able to see early-stage or treatment-naďve patients?

Read full article... Read full article...

 


Companies

Friday, April 25, 2014

Biotech Long-Term Profit Machines Stock Prices on Sale / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Market volatility has suddenly created some great opportunities, including those in the biotech sector.

Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.

Consider that since it began trading in early 2001, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) is up 130%. That's more than triple the S&P 500's 13-year return of 43%.

Read full article... Read full article...

 


Companies

Friday, April 18, 2014

Build Biotech Wealth on Solid Platforms / Companies / BioTech

By: TLSReport

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

The Life Sciences Report: As an analyst you focus on promising junior biotechs. What primary qualities do you look for in a company that you rate hold or outperform? And what do you think makes a junior biotech attractive to someone who might want to acquire it?

Read full article... Read full article...

 


Companies

Thursday, April 17, 2014

Hidden Australian Life Sciences Bio-tech Growth Stocks / Companies / BioTech

By: TLSReport

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement.

The Life Sciences Report: You are based in Brisbane, Australia, where your firm, Morgans Financial, is headquartered. All the names on your coverage list have traded on the Australian Securities Exchange (ASX). How would you compare investing in Australian biotech or medtech stocks to investing in those same types of stocks in the U.S. or Europe?

Read full article... Read full article...

 


Companies

Wednesday, April 16, 2014

There Is No Biotech Stock Bubble; Here's the Real Story / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

But they're wrong; the market is simply in a period of adjustment.

The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

Read full article... Read full article...

 


Companies

Friday, April 11, 2014

Don't Miss the Boat on Big Biotech Catalysts: Keith Markey / Companies / BioTech

By: TLSReport

Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar is positively glowing with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects and one medical device and supply company with serious growth potential. Be warned—huge catalysts are on the horizon that investors won't want to miss.

Read full article... Read full article...

 


Companies

Monday, April 07, 2014

Biotech Investing - Finding the Blockbuster That Will Make You Rich / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.

It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.

So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.

Read full article... Read full article...

 


Companies

Friday, February 28, 2014

Investors Should Evaluate Biotech Stocks with Cynicism / Companies / BioTech

By: TLSReport

Biotech investing is a risky business, so investors should thoroughly examine a company's vital statistics before taking the plunge. That's the recommendation of Managing Director Debjit Chattopadhyay of Emerging Growth Equities, who brings a strict scientific discipline to stock analysis. As a former medical researcher, Chattopadhyay comes by his skepticism honestly, and in this interview with The Life Sciences Report, he brings five exciting—but critically scrutinized—growth names to investors' attention.

Read full article... Read full article...

 


Commodities

Friday, February 14, 2014

Big Pharma Will Find Good Hunting Among Early-Stage Biotechs Stocks / Commodities / BioTech

By: TLSReport

Dhesh Govender, manager of the life sciences portfolio for Cedar Lane Enterprises Inc., has the inside track when it comes to identifying the hottest biotech trends. In this interview with The Life Sciences Report, Govender explains why he thinks plenty of upside remains in the life sciences sector, and reveals trade secrets that every investor should consider when building a successful investment strategy.

Read full article... Read full article...

 


Companies

Wednesday, February 12, 2014

Regenerative Medicine Finally Gets Some Respect / Companies / BioTech

By: TLSReport

Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life Sciences Report, Reni Benjamin, managing director and equity research analyst at H.C. Wainwright & Co., talks about two companies with impending catalysts that play on these themes, and offers his take on the prospects for the regenerative medicine sector going forward.

Read full article... Read full article...

 


Companies

Friday, January 17, 2014

New Way to Make Big Money in Biotech Stocks Sector / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: Traditional pharmaceutical blockbusters like Pfizer's Lipitor treat millions of patients at relatively low cost. It's a high-volume business model that has kept the pharmaceutical industry afloat for a long, long time. But over the past decade, out of necessity, a new model has taken the industry by storm.

As big moneymakers, like Lipitor, reach the "patent cliff," their intellectual rights protection are evaporating, and generic drug makers are taking over their markets.

Read full article... Read full article...

 


Stock-Markets

Sunday, January 05, 2014

Transformative Human Biotech Revolution Forecast 2014 / Stock-Markets / BioTech

By: John_Mauldin

It is that time of the year when we peer into our darkened crystal balls in hopes of seeing portents of the future in the shadowy mists. This year I see three distinct wisps of vapor coalescing in the coming years. Each deserves its own treatment, so this year the annual forecast issue will in fact be three separate weekly pieces.

The final letter of the series will discuss what I see as potentially developing in the markets this year, but such prognostication has to be framed within the context of two larger and far more important streams. Next week we will examine the larger economic problems facing much of the developed world, and specifically we'll consider the Era of Unfulfilled Expectations. What happens when governments and central banks find it impossible to live up to the promises that they have made to their constituencies? Throw in a mix of frustrating demographics and disastrous economic policy choices, and you have a witch's brew of uncertainties.

Read full article... Read full article...

 


Companies

Thursday, December 26, 2013

Coming of Age: Experts Reflect on the Extraordinary Promise of the Cell Therapy Sector / Companies / BioTech

By: TLSReport

Without innovation and risk-taking, modern medicine would be missing staples of the physician's armamentarium: antibiotics, radiation therapies, vaccines. The idea of taking a tonic to cure what ails you is thousands of years old, but the science behind that tonic may be revolutionary. Enter stem cell technologies. Given the promise backing the science—and the sector's position on the cusp of breaking out—companies with cell therapies got plenty of attention from investment analysts and experts in 2013. Read what those experts, including George Zavoico of MLV & Co., Steve Brozak of WBB Securities, Jason Kolbert of the Maxim Group, and Kevin DeGeeter of Ladenberg Thalmann & Co., had to say about prospects for stem cell companies in this special retrospective article from The Life Sciences Report.

Read full article... Read full article...

 


Companies

Friday, December 13, 2013

Biotech Growth Stocks Investing / Companies / BioTech

By: TLSReport

Get ready for a bonanza of biotech names. Managing Director and Equity Research Analyst Reni "Ren" Benjamin is a new arrival at H.C. Wainwright & Co., and he's busy doing diligence on a lot of stocks. Along with three Buy-rated biotechs he's already initiated coverage on, Benjamin brought The Life Sciences Report a bonus package of names that could fatten investors' portfolios. Backed by Benjamin's extensive industry knowledge, this long shopping list includes companies poised to make drug development history.

The Life Sciences Report: Do you currently have a major theme, Ren, or do you just go anywhere to find growth?

Read full article... Read full article...

 


Companies

Wednesday, December 04, 2013

Cutting Through the Biotech Stocks Hype / Companies / BioTech

By: Investment_U

Marc Lichtenfeld: When a woman, claiming to be the wife of a deceased general from Nigeria, writes to us saying she needs our help getting $10 million out of the country and in return we’ll get 20% of the money, most of us know that’s a load of bull.

But when the CEO of a publicly traded biotech company tells us his drug is the next great thing? How do we know if he’s being truthful, hopeful or just a plain scam artist?

Read full article... Read full article...

 


Page << | 1 | 2 | 3 | 4 | 5 | 6 | 7 | >>